Lumida
/AMN
⌘K
AMN Healthcare Services Inc

AMN Healthcare Services Inc

AMN
$33.34USD↑+0.88%+0.29 today

MARKET CAP

1.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$33 – $34

52W RANGE

$15
$37

AI Summary

Stalk
StalkMedium

AMN remains in a Stage 2 markup within a solid long-term uptrend. Price is consolidating between support and resistance near the short- and mid-term EMAs, with neutral momentum and declining volume arguing for patience before committing. We will defer buying until either a clear breakout above the recent highs is confirmed or a shallow pullback into the rising EMA zone is absorbed, aligning with the High Momentum strategy’s emphasis on shallow retracements into trend continuation.

  • ↑Q2 revenue $673M and adjusted EPS $0.77 exceeded guidance; positive earnings revisions.
  • ↑Nurse & Allied Solutions revenue $422M, up 11% YoY, shows strong segment demand.
  • ↓Negative profitability metrics highlight operational inefficiency and low returns.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

AMN Healthcare Services Inc. (NYSE: AMN) is a prominent player in the healthcare staffing sector, specializing in providing healthcare workforce solutions across various disciplines, including nursing and allied health. With a market capitalization of approximately $1.19 billion, AMN is positioned to meet the growing demands of an aging population and the ongoing healthcare workforce challenges, making it integral to the broader healthcare ecosystem.

Bull says

  • ↑Q2 revenue $673M and adjusted EPS $0.77 exceeded guidance; positive earnings revisions.
  • ↑Nurse & Allied Solutions revenue $422M, up 11% YoY, shows strong segment demand.
  • ↑Favorable valuation: high earnings yield and book-to-price ratio of 2.31x.
  • ↑Strong liquidity with $362M cash against $750M debt underpins flexibility.
  • ↑Macro tailwinds from an aging population and chronic diseases sustain staffing demand.
  • ↑High quality metrics and low volatility suggest a stable investment profile.

Bear says

  • ↓Negative profitability metrics highlight operational inefficiency and low returns.
  • ↓Sluggish growth outlook: Q3 guidance of $640–655M implies potential stagnation.
  • ↓High short interest and falling institutional ownership signal skepticism.
  • ↓Elevated book-to-price ratio of 2.31x may reflect overvaluation risk.
  • ↓Labor market strains and physician shortages could disrupt service delivery.
  • ↓Lack of momentum and low dividend yield limit near-term upside potential.

Investment themes with AMN

Health Care Providers↓ -0.37%

UNH · CVS · HCA

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 02-21-2025neutral

Transcript signals

Bull points

  • So we took early actions around expenses to make sure that we were coming down as the market was coming down. And we also made some very strategic capital investments, both in our systems but also in MSDR and growing parts of the market and bought back $425 million in shares. So I am very pleased with what we did both in getting through the reset and positioning ourselves more strongly for 2024 and 2025.
  • During 2023, if we look at Q4, year-over-year Q4, our internal fill rate for MSPs went up 450 basis points. So we have seen as demand has gone down, we've seen our internal capture go up. And we would expect that to continue in 2024.
  • We continue to see and we expect locums to have continued strong demand in 2024. And that's really more of an industry phenomenon than just an AMN phenomenon.

Bear points

  • Consolidated revenue was down 27% from the fourth quarter of 2022.
  • Gross margin for the quarter was 31.9%, slightly below our guidance range, primarily due to lower bill pay spreads in the Nurse and Allied business and less VMS revenue.
  • Compared with the prior year period, gross margin was down 140 basis points. Sequentially, gross margin decreased 200 basis points, primarily due to lower Nurse and Allied margin and an unfavorable revenue mix shift in Technology and Workforce Solutions.
Read full transcript analysis ›